- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
Adding in Stem Cell Therapy Helps Beat a Common Childhood Leukemia
Combining stem cell transplants with cutting-edge immunotherapy prevents leukemia relapses in young people and improves their chances of survival, new research suggests.
Acute lymphoblastic leukemia is the most common childhood cancer.
This study included 50 patients (ages: 4 to 30) with acute lymphoblastic leukemia who received CAR T-cell therapy. The treatment genetically modifies a patient’s own immune cells to make them more effective at killing cancer. (CAR is shorthand for chimeric antigen receptor.)
While CAR-T cell therapy provides complete remission in between 60% and 100% of patients initially, many relapse. One study found that more than 40% had relapsed 13 months after treatment.
This study investigated whether stem cell transplants could help prevent relapses in patients who had undergone CAR T-cell treatment.
Of 21 patients who received a transplant of donor stem cells after CAR T-cell therapy, 9.5% had relapsed 24 months later, the study found. All of the patients who didn’t have a stem cell transplant had relapsed by that point.
The findings — published recently in the Journal of Clinical Oncology — suggest that stem cell transplants offer long-term benefits for young patients who get CAR T-cell therapy, according to the University of Virginia researchers.
“More than 50% of kids in other studies with a different CAR relapse, with the majority of them losing the target the CAR goes after,” said Dr. Daniel Lee, a pediatric oncologist and director of Pediatric Stem Cell Transplant and Immunotherapy at UVA Children’s Hospital in Charlottesville.
“Most of these kids have a single shot at this life-saving and paradigm-changing therapy called CAR T-cells. We should do all we can to maximize the chance for a cure, and right now that means a transplant after CAR therapy for most,” Lee added.
He noted that many parents turn to CAR T-cells in hopes of avoiding a stem cell transplant.
“But,” he added, “there is a window of opportunity after CARs to cure more of these incurable kids with a transplant; our study demonstrates this.”
More information
The American Cancer Society has more on acute lymphoblastic leukemia.
SOURCE: University of Virginia, news release, March 31, 2021
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.